The purpose ofthe Training and Career Development Program ofthe Primary Immune Deficiency Treatment Consortium (PIDTC) is to provide career development that will enhance educafion at the clinical postdoctoral level. By training investigators specifically in the area of PID, the cadre of physician-scienfists involved in elucidating the pathogenesis ofthese disorders and developing and applying improved therapies will be augmented. Clinical invesfigators caring for pafients with PID require a complex set of skills, including knowledge of immune reconstitufion and transplant immunology, diagnosis and medical management of pafients with PID, and expertise in hematology, infecfious diseases, genefics and critical care of ill pafients undergoing hematopoietic cell transplantafion (HCT). They also need to familiarize and interactwith PID Pafient Advocacy Groups. The PIDTC brings together specialists from North America and provides a unique platform to train new investigators in the course of disseminating knowledge to providers, patients and families. The goal of PIDTC training grants is to provide support for research at the level ofthe clinical post-doctoral fellow. Our experience with the first four years of awardees reinforces much of what we plan for the next cycle. We have seen the benefits of networking and formal presentations and propose to enhanceihat type of participafion. We have also noted the challenges faced by those who plan an academic career but this is an especially acute issue in the field of PIDs, where the study of rare diseases often requires a network of invesfigators, a difficult proposifion for junior faculty.
The Specific Aims of this Program are to (1) select the highest quality candidates for training support in Primary Immune Deficiency research, (2) incorporate the supported Fellows into PIDTC activities to enhance their education and networking opportunities, and (3) continue to track the outcome of training of supported fellows, based on scientific publications and career advancement. The PIDTC provides a network of committed invesfigators with specific expertise in the biology, diagnosis and treatment of PIDs, and will serve as an important training ground for emerging investigators. The structure ofthe PIDTC consortium will facilitate the development of junior invesfigators studying immune deficiencies.

Public Health Relevance

The PIDTC Training program is focused on providing small research grants to support fellows and junior faculty in research in primary immune deficiencies (PIDs) and to promote their academic careers. The Training program sfimulates interest in PIDs and encourages participation in all aspects ofthe PIDTC.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZTR1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
San Francisco
United States
Zip Code
Burbank, Allison J; Shah, Shaili N; Montgomery, Maureen et al. (2016) Clinically focused exome sequencing identifies an homozygous mutation that confers DOCK8 deficiency. Pediatr Allergy Immunol 27:96-8
Cowan, Morton J (2016) The Primary Immune Deficiency Treatment Consortium: how can it improve definitive therapy for PID? Expert Rev Clin Immunol 12:1007-9
Griffith, Linda M; Cowan, Morton J; Notarangelo, Luigi D et al. (2016) Primary Immune Deficiency Treatment Consortium (PIDTC) update. J Allergy Clin Immunol 138:375-85
Chan, Alice Y; Punwani, Divya; Kadlecek, Theresa A et al. (2016) A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70. J Exp Med 213:155-65
De Ravin, Suk See; Wu, Xiaolin; Moir, Susan et al. (2016) Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency. Sci Transl Med 8:335ra57
Jackson, Shaun W; Scharping, Nicole E; Jacobs, Holly M et al. (2016) Cutting Edge: BAFF Overexpression Reduces Atherosclerosis via TACI-Dependent B Cell Activation. J Immunol 197:4529-4534
Punwani, Divya; Kawahara, Misako; Yu, Jason et al. (2016) Lentivirus Mediated Correction of Artemis-deficient Severe Combined Immunodeficiency. Hum Gene Ther :
Punwani, Divya; Zhang, Yong; Yu, Jason et al. (2016) Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B. N Engl J Med 375:2165-2176
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Chinen, Javier; Notarangelo, Luigi D; Shearer, William T (2016) Advances in clinical immunology in 2015. J Allergy Clin Immunol 138:1531-1540

Showing the most recent 10 out of 64 publications